This report provides all the information you require to better understand Menarini and its partnering interests and activities over the past seven years.
Menarini has announced 2 M&A deals since 2005, with the deals being the acquisition of Invida Holdings and Silicon Biosystems.
Smaller, more targeted deals may be the way of the future as big pharma partnering seeks to outsource early stage R&D and risk
Analysis of data from the leading life science deals and alliances intelligence database Current Agreements and recently published Partnering Yearbook 2013 report series, shows that the top twenty partnering deals in the life sciences have a combined value of $20.6 billion
This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in October 2012
Pharma news reports that, As Spain’s economy was booming more than a decade ago, drugmaker Almirall SA (ALM) decided it was time to boost international sales, treading a path that other companies are now following to offset health cuts in the debt-ravaged country
Sorry, your search returned no results.
VIVUS enters pharma deals with big pharma Menarini for license of SPEDRA in over 40 European countries plus Australia and New Zealand and supply agreement.